SBT-272 Supports Health of Mitochondria in ALS Mouse Model

SBT-272 Supports Health of Mitochondria in ALS Mouse Model

309016

SBT-272 Supports Health of Mitochondria in ALS Mouse Model

An investigational treatment for amyotrophic lateral sclerosis (ALS), SBT-272 was found to sustainably reach different brain regions, and to protect mitochondria — a cell’s energy source — from TDP-43 toxic aggregates in a mouse model of the disease. “We are excited about the promise of SBT-272 as a potential therapeutic for neurodegenerative diseases including ALS,” Reenie McCarthy, CEO of Stealth BioTherapeutics, the therapy’s developer, said in a press release. The company plans to launch dose-finding Phase 1 studies…

You must be logged in to read/download the full post.